Latest News and Press Releases
Want to stay updated on the latest news?
-
BOSTON, MA--(Marketwired - Feb 22, 2017) - InCrowd, a provider of real-time market intelligence to the life sciences and healthcare firms, introduces MicroQual, a qualitative research solution that...
-
BOSTON, MA--(Marketwired - Jan 3, 2017) - As a new President-Elect takes office with plans to dismantle much of the existing Affordable Care Act (ACA), US physicians are strongly pessimistic that...
-
BOSTON, MA--(Marketwired - Nov 16, 2016) - As the FDA approves more biosimilars -- lower cost, similar yet not identical versions of already approved biologic drugs -- a notably larger percentage...
-
BOSTON, MA--(Marketwired - Nov 10, 2016) - US physicians who prescribe opioid pain medications are owning their role in today's opioid abuse while citing structural problems that feed the issue,...
-
BOSTON, MA--(Marketwired - Nov 2, 2016) - US nurses are profoundly dissatisfied with both major political party candidates for President when it comes to their ability to be successful in improving...
-
BOSTON, MA--(Marketwired - Oct 28, 2016) - As the topic of sexual assault gets continued examination via the US Presidential election, new data about US psychiatrists and psychologists' discussions...
-
BOSTON, MA--(Marketwired - Apr 26, 2016) - Despite the onset of spring and the reemergence of mosquitos, 20% of pregnant or would-be pregnant women polled in the US in April still have not heard...
-
BOSTON, MA--(Marketwired - Apr 25, 2016) - InCrowd, a provider of real-time market intelligence to healthcare and life sciences firms, today announced that it has been included in the "Cool Vendors...
-
BOSTON, MA--(Marketwired - Mar 30, 2016) - As the healthcare industry celebrates National Doctors Day today, InCrowd, a provider of real-time market intelligence to healthcare and life sciences...
-
BOSTON, MA--(Marketwired - Mar 3, 2016) - In a new MicroSyndicated survey from InCrowd, targeted US biologics prescribers shared their perceptions regarding the onset of biosimilars -- lower cost,...